| Chapter title |
Should We De-escalate the Treatment for HPV-Positive Tumors?
|
|---|---|
| Chapter number | 13 |
| Book title |
HPV Infection in Head and Neck Cancer
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, October 2016
|
| DOI | 10.1007/978-3-319-43580-0_13 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-943578-7, 978-3-31-943580-0
|
| Authors |
Andreas Dietz, Gunnar Wichmann, Susanne Wiegand |
| Editors |
Wojciech Golusiński, C. René Leemans, Andreas Dietz |
| Abstract |
De-escalation or de-intensification of therapy is discussed since many retrospective analyses of former trials demonstrated significantly better outcome for patients suffering from p16/HPV16-positive oropharyngeal squamous cell carcinoma of head and neck (OHNSCC). These observations are comprehensively addressed, but the reader has to keep in mind that none of the currently discussed data result from prospective controlled trials addressing the HPV-discrimination in the primary endpoint design. Identification of the true HPV16-related tumors is still challenging and in addition with different clinical reports and lack of data of prospective trials not mature for routine clinical decision making in 2016. Independent of the currently lacking evidence for HPV-dependent treatment de-escalation, there are some relevant arguments to address this question in ongoing and future trials. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 5 | 18% |
| Researcher | 4 | 14% |
| Student > Master | 3 | 11% |
| Student > Bachelor | 3 | 11% |
| Other | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 9 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 43% |
| Nursing and Health Professions | 2 | 7% |
| Arts and Humanities | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 9 | 32% |